Sol-Gel Technologies Ltd. (SLGL)
Market Cap | 109.59M |
Revenue (ttm) | 3.88M |
Net Income (ttm) | -14.92M |
Shares Out | 25.70M |
EPS (ttm) | -0.65 |
PE Ratio | n/a |
Forward PE | 9.34 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 61,815 |
Open | 4.30 |
Previous Close | 4.22 |
Day's Range | 4.22 - 4.48 |
52-Week Range | 3.24 - 7.95 |
Beta | 1.32 |
Analysts | Buy |
Price Target | 12.75 (+198.95%) |
Earnings Date | May 11, 2023 |
About SLGL
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, w... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for SLGL stock is "Buy." The 12-month stock price forecast is $12.75, which is an increase of 198.95% from the latest price.
News

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an i...

7 Biotech Stocks That Could Be the Next Big Thing
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that c...

Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022.

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an i...

The Top 7 Penny Stocks to Invest in for the Long-Term
Typically, penny stocks represent pure market wagers appropriate only for hardened gamblers. However, every once in a blue moon, a few ideas pop up in this segment that may be worth a genuine investme...

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two inn...

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products...

3 Generic Drug Stocks to Watch Amid Inflation Pressures
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.

SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022.

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 90% and 27.46%, respectively, for the quarter ended June 2022.

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
NESS ZIONA, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 20% and 99.85%, respectively, for the quarter ended March 2022.

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
NESS ZIONA, Israel, May 13, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gene...

Earnings Preview: SolGel Technologies Ltd. (SLGL) Q1 Earnings Expected to Decline
SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
NESS ZIONA, Israel and ZUG, Switzerland, April 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing bran...

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®
NESS ZIONA, Israel, April 14, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topic...

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments
NESS ZIONA, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topic...

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
TWYNEO will be officially launched for commercial availability in Spring 2022. TWYNEO will be officially launched for commercial availability in Spring 2022.

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference
NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and...

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®
NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topica...

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
NESS ZIONA, Israel, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topica...

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topica...